Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytomX Therapeutics Inc | CTMX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.63 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.63 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.04 - 2.855 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.63 | USD |
CytomX Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 110.39M | 67.72M | - | 101.21M | -569k | -0.01 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CytomX Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTMX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.77 | 1.7875 | 1.62 | 1.67 | 320,676 | -0.14 | -7.91% |
| 1 Month | 2.20 | 2.30 | 1.62 | 2.05 | 645,442 | -0.57 | -25.91% |
| 3 Months | 1.53 | 2.855 | 1.41 | 2.26 | 977,055 | 0.10 | 6.54% |
| 6 Months | 1.22 | 2.855 | 1.04 | 2.06 | 612,243 | 0.41 | 33.61% |
| 1 Year | 1.62 | 2.855 | 1.04 | 1.93 | 448,496 | 0.01 | 0.62% |
| 3 Years | 9.22 | 10.05 | 1.04 | 2.97 | 1,013,229 | -7.59 | -82.32% |
| 5 Years | 9.94 | 15.44 | 1.04 | 4.31 | 821,632 | -8.31 | -83.60% |
CytomX Therapeutics Description
| CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities. |
